Company facts
- Headquarters
- Westbrook, Maine
- Most recent report
- 10-Q, filed Nov 2, 2026
- Incorporated
- Delaware
- Filings on record
- 1,000+ filings
- On EDGAR
- CIK 874716
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 48
News 8 of 107
Prospectuses and Registrations 3
Proxies 8 of 27
- DEFA14A Extra proxy material Mar 27, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2026
- PRE 14A Preliminary proxy statement Mar 13, 2026
- DEFA14A Extra proxy material Mar 28, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 28, 2025
- PRE 14A Preliminary proxy statement Mar 14, 2025
- DEFA14A Extra proxy material Mar 27, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2024
Ownership 8 of 783
- 4 Insider reported a trade Nov 5, 2026
- 4 Insider reported a trade Nov 5, 2026
- 4 Insider reported a trade Nov 5, 2026
- 4 Insider reported a trade Nov 5, 2026
- 144/A Notice of a proposed sale of restricted stock, amended Nov 5, 2026
- 144 Notice of a proposed sale of restricted stock Nov 4, 2026
- 144 Notice of a proposed sale of restricted stock Nov 4, 2026
- 144 Notice of a proposed sale of restricted stock Nov 4, 2026
Other 8 of 32
- SD Conflict minerals disclosure Jun 1, 2026
- ARS Annual report sent to shareholders Mar 27, 2026
- UPLOAD Comment letter from SEC staff Jul 7, 2025
- CORRESP Reply to SEC staff Jun 2, 2025
- SD Conflict minerals disclosure May 30, 2025
- UPLOAD Comment letter from SEC staff May 21, 2025
- CORRESP Reply to SEC staff Apr 30, 2025
- UPLOAD Comment letter from SEC staff Apr 24, 2025
What to read: Sep 2026 10-Q
SECSift found 3 of 11 sections worth reading, with 0 positive, 11 notable, and 2 negative flags.
Financial Statements (Item 1)
Financial statements and notes with acquisition, debt, buyback, and litigation details.NotableManagement's Discussion (Item 2)
Full MD&A with segment results, cash flows, debt details, and a litigation payment.Notable- The company acquired software business CoVet on September 15, 2026; impact was immaterial for the period.
- Interest expense fell to $7.5M in Q3 2026 from $10.7M, due to lower average debt levels.
- General & administrative expense rose 16.4% in Q3 2026, partly from a $5M equity investment impairment in Q1.
- Working capital fell to $235.8M from $265.0M at year-end, due to higher credit facility borrowings.
- Share repurchases dropped by $169.2M in the nine months ended September 30, 2026 vs prior year.
- Leverage ratio was 0.5x as of September 30, 2026, well below the 3.5x covenant limit.
Market Risk (Item 3)
Quantified FX impacts on revenue, profit, EPS; new interest rate swap; inflation risks.Notable
What changed: Sep 2026 vs. Jun 2026
About 9% of IDXX's Sep 2026 10-Q is new information. 27 paragraphs were added, 166 changed, and 36 removed. Below are the most important lines SECSift identified.
Changed
- Credit Facility borrowings fell to $474.0M from $519.0M; repaid $75M senior notes.
- Contingent consideration liability rose to $20.2M from $1.8M due to CoVet earnout.
- Credit Facility borrowings were $474.0 million as of September 30, 2026, up from $398.0 million as of December 31, 2025.
- Goodwill rose to $640.5M from $410.9M due to the CoVet acquisition.
- Net income for the three months ended Sep 30, 2026 rose to $317.1M from $274.6M.
- CAG segment income from operations rose to $369,503 from $328,471 for the three months ended September 30, 2026 vs 2025.
- Interactive data file table number rose to 56 from 57, and rows changed to '101, 104' from '101, 104, *'.
- Revenue from international sales in local currencies rose to 24% and 23% for three and nine months ended Sep 30, 2026, from 23% and 22% for the same periods in 2025.
- Shares surrendered for tax withholding dropped to 275 from 529 in the prior quarter.
Everything here comes from Idexx Laboratories Inc's own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Nov 2, 2026, from the 10-Q for Sep 2026.